Revelation Biosciences Inc. Common Stock (REVB)
Stock · NASDAQ · Health Care
$0.4776as of 10/16/2026
Price chart
Active signals
REVB Signal Track Record
How signals performed across all stocks →What REVB's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 21 | -13.4% | 33% | September 24, 2026 |
| Bollinger Band Breakout | 18 | -21.6% | 0% | July 16, 2026 |
| Volume SpikeActive now | 15 | -12.0% | 27% | October 1, 2026 |
| Any 20-session window (baseline) | -12.8% | 23% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About REVB
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory res…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 8
- Website
- www.revbiosciences.com/
Fundamentals
- 1-day range
- $0.4704$0.705
- Market cap
- $4.38M
- P/E (trailing)
- 0.04
- P/E (forward)
- -0.16
- EPS (trailing)
- $-6.33
- Dividend yield
- —
- Beta
- -0.14
- Avg. volume
- 34.1K
Forecasts
2 analyst ratings
Revelation Biosciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- REVBRevelation Biosciences Inc. Common Stock$0.485▼ 36.35%Market cap $4.38MP/E 0.04$0.71$5.8
- ELABPMGC Holdings Inc. Common Stock$2.77▼ 8.88%Market cap $4.34MP/E —$2.59$2,671
- DRMADermata Therapeutics Inc. Common Stock$0.86▼ 5.49%Market cap $4.46MP/E —$0.6032$4.66
- JUNSJupiter Neurosciences Inc. Common Stock$2.9▼ 7.48%Market cap $4.24MP/E —$2.25$135.75
- RNAZTransCode Therapeutics Inc. Common Stock$1.7▼ 5.56%Market cap $4.52MP/E —$1.52$15.94
- JAGXJaguar Health Inc. Common Stock$3.53▼ 23.20%Market cap $4.61MP/E —$2.35$1,268
- INMInMed Pharmaceuticals Inc. Common Shares$1.32▼ 0.75%Market cap $4.01MP/E —$0.575$2.33
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| REVB Revelation Biosciences Inc. Common Stock | $4.38M | 0.04 | $0.485 | ▼ 36.35% | $0.71$5.8 |
| ELAB PMGC Holdings Inc. Common Stock | $4.34M | — | $2.77 | ▼ 8.88% | $2.59$2,671 |
| DRMA Dermata Therapeutics Inc. Common Stock | $4.46M | — | $0.86 | ▼ 5.49% | $0.6032$4.66 |
| JUNS Jupiter Neurosciences Inc. Common Stock | $4.24M | — | $2.9 | ▼ 7.48% | $2.25$135.75 |
| RNAZ TransCode Therapeutics Inc. Common Stock | $4.52M | — | $1.7 | ▼ 5.56% | $1.52$15.94 |
| JAGX Jaguar Health Inc. Common Stock | $4.61M | — | $3.53 | ▼ 23.20% | $2.35$1,268 |
| INM InMed Pharmaceuticals Inc. Common Shares | $4.01M | — | $1.32 | ▼ 0.75% | $0.575$2.33 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Chester Stanley Zygmont III · August 17, 2026 · Gift208.1K
- Chester Stanley Zygmont III · August 17, 2026 · Grant208.1K
- James Rolke · August 17, 2026 · Grant208.1K
- Jennifer Carver · August 17, 2026 · Grant32.0K
- Lakhmir S. Chawla · August 17, 2026 · Grant32.0K
- Jess Roper · August 17, 2026 · Grant32.0K
- Chester Stanley Zygmont III · April 30, 2026 · Tax Withholding13.3K @ $1.1
- James Rolke · April 30, 2026 · Tax Withholding10.1K @ $1.13
Institutional Ownership
March 31, 2026
- Total shares held
- 486.5K
- Total value held
- $584.0K
- Institutional holders
- 10
- Unknown323.2K
- Unknown99.4K
- Unknown43.2K
- Unknown11.4K
- Unknown4.1K
- Unknown4.1K
- Unknown747
- Unknown344
- Unknown9
- Unknown1
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
REVB announces 1-for-7 reverse stock split effective Oct 20
Revelation Biosciences disclosed that its common stock will undergo a 1‑for‑7 reverse split, with the change taking effect on October 20. The split will combine seven existing shares into one, reducing the total share count and raising the per‑share price proportionally. This corporate action may help the stock meet price‑level requirements and could affect the share’s liquidity. The company’s other metrics remain unchanged.
REVB announces 1-for-7 reverse stock split effective Oct 20. Revelation Biosciences disclosed that its common stock will undergo a 1‑for‑7 reverse split, with the change taking effect on October 20. The split will combine seven existing shares into one, reducing the total share count and raising the per‑share price proportionally. This corporate action may help the stock meet price‑level requirements and could affect the share’s liquidity. The company’s other metrics remain unchanged.